• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Halozyme Therapeutic (NQ: HALO )

    57.26 +0.29 (+0.51%)
    Streaming Delayed Price Updated: 10:01 AM EDT, Sep 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 101,315
    Open 56.87
    Bid (Size) 57.17 (4)
    Ask (Size) 57.33 (4)
    Prev. Close 56.97
    Today's Range 56.64 - 57.50
    52wk Range 32.83 - 65.53
    Shares Outstanding 142,334,900
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NASDAQ:HALO is showing good growth, while it is not too expensive.
    Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. 
    Via Chartmill
    NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals. 
    Via Chartmill

    Performance

    YTD
    +53.14%
    +53.14%
    1 Month
    -10.32%
    -10.32%
    3 Month
    +10.07%
    +10.07%
    6 Month
    +38.58%
    +38.58%
    1 Year
    +51.92%
    +51.92%

    More News

    Read More
    Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire
    (HALO) - Analyzing Halozyme Therapeutics's Short Interest
    Via Benzinga
    Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
    Via Chartmill
    Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know
    Via Benzinga
    NASDAQ:HALO is not too expensive for the growth it is showing.
    Via Chartmill
    Top 2 Health Care Stocks That May Plunge In August
    Via Benzinga
    How Is The Market Feeling About Halozyme Therapeutics?
    Via Benzinga
    NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Via Chartmill
    Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
    Via Investor's Business Daily
    Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
    Via Chartmill
    Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
    Via Chartmill
    HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    (HALO) - Analyzing Halozyme Therapeutics's Short Interest
    Via Benzinga
    Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
    Via Benzinga
    Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
    Via Chartmill
    Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
    Via Investor's Business Daily
    Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
    Via Investor's Business Daily
    NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
    Via Chartmill
    3 Biotech Stocks on Track for 50% Returns (or More) by 2028
    Via InvestorPlace
    Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
    Via Investor's Business Daily
    Beam Therapeutics Stock Earns RS Rating Jump To 85
    Via Investor's Business Daily
    NASDAQ:HALO is showing good growth, while it is not too expensive.
    Via Chartmill
    3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.